

AM26259PU-N**Monoclonal Antibody to Complement C5 - Purified****Alternate names:**

C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4, CPAMD4, Complement component 5

Quantity:

0.1 mg

Concentration:

0.1 mg/ml

Background:

The complement system is composed of over 30 proteins, activated in response to tissue injury, invading pathogens or other foreign surfaces. The complement pathways can be divided in the activation pathways and lytic pathway. The activation pathways lead via C3 to the cleavage of the fifth complement component C5. C5a was first described as a cleavage product of C5 with chemotactic and anaphylatoxic properties. Further characterization revealed that C5a is an essential part of the innate immune response and evidence now suggests that it may also play a role in adaptive immunity. Complement fragment C5a is a 74 residue pro-inflammatory polypeptide. C5a induces smooth muscle contraction, increases vascular permeability, causes degranulation of mast cells and basophils, and release of lysosomal enzymes. In addition C5a stimulates the directed migration of neutrophils, eosinophils, basophils and monocytes. C5a binds to at least two seven-transmembrane domain receptors, C5aR (C5R1, CD88) and C5L2 (gpr77), expressed ubiquitously on a wide variety of cells but particularly on the surface of immune cells like macrophages, neutrophils and T cells. The former is a well-established receptor that initiates G-protein-coupled signaling via mitogen-activated protein kinase pathways, thereby by inducing synthesis of cytokines such as TNF-alpha, IL-1beta, IL-6 and IL-8. Its in vivo blockade greatly reduces inflammatory injury. Much less is known about C5L2, occupancy of which by C5a does not initiate increased intracellular Ca(2+). The widespread expression of C5a receptors throughout the body allows C5a to elicit a broad range of effects. Thus, C5a has been found to be a significant pathogenic driver in a number of immuno-inflammatory diseases. Nowadays C5a is also implicated in non-immunological functions associated with developmental biology, CNS development and neurodegeneration, tissue regeneration, and haematopoiesis.

Uniprot ID:

[P01031](#)

NCBI:

[9606](#)

GeneID:

[727](#)

Host / Isotype:

Mouse / IgG2a

Recommended Isotype

AM03096PU-N

Controls:**Clone:**

557

Immunogen:

Human C5

Format:	State: Liquid 0.2 µm filtered Ig fraction Purification: Protein G Buffer System: PBS Preservatives: 0.02% sodium azide Stabilizers: 0.1% bovine serum albumin
Applications:	Functional assays: Product must be filter sterilized and depending on the concentration to be used dialyzed against culture medium to remove the sodium azide added. Immunoassays (1,2,3): Detection antibody in ELISA. (Ref.1). Western blot (1): Used as ascites at a 1/1000 dilution. Incubation 2h on nitrocellulose blotted samples. (Ref.1). Positive control: Recombinant C5. Negative control: Recombinant C5. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Specificity:	The monoclonal antibody 557 recognizes an epitope of complement factor 5 (C5) and C5a. It is capable to inhibit the binding of C5a to the C5a receptor through a competitive mechanism, it does not block the cleavage of C5 into C5a and C5b.
Species Reactivity:	Tested: Human
Storage:	Store at 2 - 8 °C. Shelf life: one year from despatch.
General Readings:	1. Klos A, Ihrig V, Messner M, Grabbe J, Bitter-Suermann D. Detection of native human complement components C3 and C5 and their primary activation peptides C3a and C5a (anaphylatoxic peptides) by ELISAs with monoclonal antibodies. J Immunol Methods. 1988 Jul 22;111(2):241-52. PubMed PMID: 3260926. 2. Kola A, Baensch M, Bautsch W, Hennecke M, Klos A, Casaretto M, et al. Epitope mapping of a C5a neutralizing mAb using a combined approach of phage display, synthetic peptides and site-directed mutagenesis. Immunotechnology. 1996 Jun;2(2):115-26. PubMed PMID: 9373320. 3. Kola A, Baensch M, Bautsch W, Klos A, Köhl J. Analysis of the C5a anaphylatoxin core domain using a C5a phage library selected on differentiated U937 cells. Mol Immunol. 1999 Feb;36(2):145-52. PubMed PMID: 10378686.